3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, T-Cell, Peripheral
2
Recurrence
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
15
romidepsin
9
Whole-Body Irradiation
9
fludarabine phosphate
8
Vincristine
8
Etoposide
8
Doxorubicin
8
Prednisone
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
7
Brentuximab Vedotin
6
10-propargyl-10-deazaaminopterin
6
Rituximab
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Cyclosporine
5
denileukin diftitox
4
Nivolumab
4
Lenalidomide
4
mogamulizumab
3
Tacrolimus
3
Methotrexate
3
Immunohistochemistry
3
Gene Expression Profiling
3
Dexamethasone
3
Alemtuzumab
3
selinexor
2
pembrolizumab
2
pegfilgrastim
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell, Peripheral
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts
NCT04101331
2024-11-05
REDIRECT
Affimed GmbH
Phase 2
Completed
108 enrolled
24 charts